Lumida
/HCAT
⌘K
Health Catalyst Inc

Health Catalyst Inc

HCAT
$1.70USD↓-1.73%-0.03 today

MARKET CAP

127.9M

P/E (TTM)

8.6x

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
StalkMedium

HCAT is in a Stage 2 advance with clear higher highs and higher lows and rising short-term EMAs, but price is extended above EMAs and overbought in the short term. Medium-term bias remains bullish after the recent breakout, yet execution should wait for a pullback into the rising 9/20 EMA zone or the lower portion of the breakout range before participation.

  • ↑Q2 revenue $70.5M topped guidance; adjusted gross margin rose to 51% YoY
  • ↑VitalWare divestiture cut $160M debt and $19M in annual interest expense
  • ↓Consensus FY26 EPS cut to –$2.41 and revenue down to $247.4M from $268.2M
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Health Catalyst, Inc. (NASDAQ: HCAT) is a leading provider of data and analytics solutions to healthcare organizations. The company primarily operates within the healthcare analytics sector, focusing on improving operational and clinical outcomes through technology-driven transformations. Recently, Health Catalyst has undergone significant strategic shifts, including the divestiture of its VitalWare segment, which has refocused its efforts on its core capabilities, particularly in AI-driven healthcare analytics and interoperability solutions.

Bull says

  • ↑Q2 revenue $70.5M topped guidance; adjusted gross margin rose to 51% YoY
  • ↑VitalWare divestiture cut $160M debt and $19M in annual interest expense
  • ↑$103.4M cash on hand enables targeted AI-analytics and interoperability investment
  • ↑Investing in AI-driven automation positions firm for high-margin analytics growth
  • ↑Strong institutional backing evident in elevated 13F ownership percentage
  • ↑Deep domain expertise and integrated analytics solutions may outpace peers

Bear says

  • ↓Consensus FY26 EPS cut to –$2.41 and revenue down to $247.4M from $268.2M
  • ↓Platform migration churn has erased $12.5M in ARR; $52M further at risk
  • ↓High share-price volatility raises downside risk amid negative sentiment
  • ↓Profitability weak and leverage elevated; low earnings yield signals inefficiency
  • ↓Price targets trimmed from $2.31 to $1.83 amid cautious market outlook
  • ↓Negative growth and quantitative factor trends underscore near-term headwinds

Investment themes with HCAT

Demographics Elective Health + Family Care↓ -0.20%

Health services for families and elective treatments

HQY · DOCS · PRVA

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-09-2025bullish

Transcript signals

Bull points

  • We are encouraged by our first quarter 2024 financial results, including total revenue of $74.7 million and adjusted EBITDA of $3.4 million, with these results above the midpoint of our most recent guidance on each metric.
Read full transcript analysis ›